Evidence map›Paper›PMID 39497542›Full record

ArticleAIDS (London, England)2025

Medical mistrust and vaccine-hesitant attitudes explain SARS-CoV-2 vaccination disparities in a mixed serostatus cohort.

M Reuel Friedman, Gina Wingood, Kristen D Krause, Sarah Krier, Gypsyamber D'Souza, Mirjam-Colette Kempf, Matthew J Mimiaga, Jenn Kwait, Deborah L Jones, Jeremy Martinson and 8 more

Abstract readMulticenter Study
In one paragraph

Article in AIDS (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

M Reuel FriedmanDepartment of Urban-Global Public Health, School of Public Health, Rutgers University, Newark, NJ.
Gina WingoodDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, New York City, NY.
Kristen D KrauseDepartment of Urban-Global Public Health, School of Public Health, Rutgers University, Newark, NJ.
Sarah KrierDepartment of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Gypsyamber D'SouzaDepartment of Epidemiology, School of Public Health, Johns Hopkins University, Baltimore, MD.
Mirjam-Colette KempfSchools of Nursing, Medicine and Public Health, University of Alabama-Birmingham, Birmingham, AL.
Matthew J MimiagaDepartment of Epidemiology, Fielding School of Public Health, University of California-Los Angeles, Los Angeles, CA.
Jenn KwaitWhitman-Walker Institute, Washington, DC.
Deborah L JonesDepartment of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL.
Jeremy MartinsonDepartment of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Ernesto T MarquesDepartment of Infectious Diseases and Microbiology, School of Public Health, University of Pittsburgh, Pittsburgh, PA.
Phyllis TienSchool of Medicine, University of California-San Francisco, San Francisco, CA.
Kathryn AnastosDepartment of Medicine, Albert Einstein College of Medicine, New York City, NY.
Catalina RamirezSchool of Medicine, University of North Carolina, Chapel Hill, NC.
Mardge CohenCook County Hospital, Chicago, IL.
Marlene Camacho-RiveraSchool of Public Health, State University of New York-Downstate Health Sciences University, New York City, NY.
Lakshmi GoparajuSchool of Medicine, Georgetown University, Washington, DC.
Charles R RinaldoDivision of Infectious Diseases, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Renee A. Heffron · 1988 to 2026
$84.1M
Engaging University of California Stakeholders for Biorespository ResearchUL1TR000004 · NCATS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2012 to 2015
$78.0M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Robert H Lyles · 2002 to 2026
$74.0M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Maternal Morbidity and Mortality: Risk Factors, Early Detection and Personalized InterventionUL1TR001409 · NCATS · GEORGETOWN UNIVERSITY · PI GONDRE-LEWIS, MARJORIE C, MELLMAN, THOMAS A · 2015 to 2024
$37.8M
SF Bay Area MACS/WIHS Combined Cohort StudyU01HL146242 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Bradley E Aouizerat, Jennifer Cohen Price · 2019 to 2026
$36.3M
Sex differences in the role of multi-omicsin HIV-associated carotid artery atherosclerosisU01HL146193 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Stephen J Gange, Elizabeth Topper · 2019 to 2026
$35.8M
University of Miami Developmental Center for AIDS Research (D-CFAR)P30AI073961 · NIAID · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI MARIA LUISA ALCAIDE · 2007 to 2026
$33.8M
Clinical Research Sites for the MACS/WIHS Combined Cohort Study (MACS/WIHS-CCS) - Baltimore/Wash DC Center - Admin Supplement: Vision and dual sensory loss in HIV-infected older adultsU01HL146201 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI TODD T BROWN, Joseph B. Margolick · 2019 to 2026
$33.7M
Sex differences in the role of multi-omics in HIV-associated carotid artery atherosclerosisU01HL146204 · NHLBI · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI David B. Hanna, Anjali Sharma · 2019 to 2026
$33.2M
NCATS NIH HHS KL2 TR001432NCATS NIH HHS TL1 TR001431NCATS NIH HHS UL1 TR000004NCATS NIH HHS UL1 TR001409NCATS NIH HHS UL1 TR001881NCATS NIH HHS UL1 TR003098NHLBI NIH HHS R01 HL160326NHLBI NIH HHS U01 HL146192NHLBI NIH HHS U01 HL146193NHLBI NIH HHS U01 HL146194NHLBI NIH HHS U01 HL146201NHLBI NIH HHS U01 HL146202NHLBI NIH HHS U01 HL146203NHLBI NIH HHS U01 HL146204NHLBI NIH HHS U01 HL146205NHLBI NIH HHS U01 HL146208NHLBI NIH HHS U01 HL146240NHLBI NIH HHS U01 HL146241NHLBI NIH HHS U01 HL146242NHLBI NIH HHS U01 HL146245NHLBI NIH HHS U01 HL146333NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI050410NIAID NIH HHS P30 AI073961NIMH NIH HHS P30 MH116867
6 · The paper itself

Abstract

objectivesTo understand the extent of racial disparities in SARS-CoV-2 vaccination among PWH and those vulnerable to HIV infection and to estimate the contributions of medical mistrust and vaccine-hesitant attitudes to these disparities.

designQuantitative data analyses in a racially and gender-diverse, mixed-serostatus prospective cohort, the Multicenter AIDS Cohort Study (MACS)/Women's Interagency HIV Study (WIHS) Combined Cohort Study.

methodsInterviewer-assisted questionnaires assessed SARS-CoV-2 vaccination, medical mistrust, and vaccine-hesitant attitudes from March 2021 to September 2022 ( n  = 3948). Longitudinal analyses assessed effects of sociodemographics on medical mistrust and vaccine-hesitant attitudes. A hierarchical multivariable logistic regression assessed effects of these co-factors on SARS-CoV-2 vaccination. Causal mediation models assessed whether medical mistrust mediated the relationship between Black identity and vaccine-hesitant attitudes, and vaccine-hesitant attitudes mediated the relationship between Black identity and SARS-CoV-2 nonvaccination.

resultsParticipants' mean age was 56.7; 55.3% were Black, 52.6% cisgender female, 62.6% PWH. 10.1% reported never receiving SARS-CoV-2 vaccinations (13.4% of Black and 4.5% of White participants). Black-identified participants had higher odds of nonvaccination than White participants [aOR = 1.72; 95% confidence interval (CI) 1.08-2.72]. Medical mistrust mediated the relationship between Black identity and vaccine-hesitant attitudes, accounting for 46% of the effect ( P  < 0.0001). Vaccine-hesitant attitudes mediated the relationship between Black identity and SARS-CoV-2 nonvaccination to the extent that 57.7% (95% CI 25.3-90.1%) of the disparity would be eliminated if vaccine-hesitant attitudes among Black respondents were reduced to levels reported among other racial groups.

conclusionFindings indicate a profound need to build trustworthy healthcare environments to combat medical mistrust and vaccine-hesitant attitudes in Black communities in the United States, including those affected by HIV.

Indexed as

COVID-19COVID-19 VaccinesHIV InfectionsTrustVaccination HesitancyAdultBlack or African AmericanFemaleHealthcare DisparitiesHealth Knowledge, Attitudes, PracticeHumansMaleMiddle AgedPatient Acceptance of Health CareProspective StudiesSurveys and QuestionnairesCOVID-19 Vaccines

Identifiers

PMID39497542
PMCPMC12587438

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.